

A study to evaluate the safety, tolerability, and efficacy of galicafort/navocafort/ABBV-119 combination therapy in subjects with cystic fibrosis

Submission date 28/01/2022	Recruitment status Stopped	<input type="checkbox"/> Prospectively registered
Registration date 07/03/2022	Overall study status Stopped	<input type="checkbox"/> Protocol
Last Edited 05/01/2024	Condition category Nutritional, Metabolic, Endocrine	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Cystic Fibrosis (CF) is a rare, life-threatening, genetic disease that affects the lungs and digestive system, significantly impairing the quality of life, with those affected having a median age of death at 40. The main objective of this study is to assess how safe and effective is the combination therapy of galicafort/navocafort/ABBV-119 in adult participants with CF

Who can participate?

Patients with CF, and the F508del CFTR mutation (the most common CF gene mutation)

What does the study involve?

Galicafort/navocafort/ABBV-119 combination therapy is being developed as an investigational drug for the treatment of CF. Study doctors place participants in 1 of the 4 groups, called treatment arms. Each group receives a different treatment. Around 90 adult participants with a diagnosis of CF will be enrolled in the study around approximately 35 sites worldwide. Participants in arm 1 will receive oral capsules of galicafort/navocafort dual combination for 28 days followed by galicafort/navocafort/ABBV-119 triple combination for 28 days. Participants in arms 2 and 3 will receive the galicafort/navocafort/ABBV-119 triple combination or placebo for 28 days. Participants in arm 4 will receive galicafort/navocafort/ABBV-119 triple combination therapy for 28 days. For all study arms, galicafort, navocafort, will be given once daily and ABBV-119 twice a day.

What are the possible benefits and risks of participating?

Benefits:

Not provided at time of registration

Risks:

ABBV-119 A small number of healthy volunteers who received ABBV-119 for up to 14 days had elevated blood levels of liver enzymes (ALT and AST), a possible sign of injury to the liver. The volunteers did not have any complaints along with these abnormal blood tests. The tests

returned to normal or near normal levels within the next 2 weeks. There could be a risk of side effects related to sunlight exposure or ultraviolet (UV) light exposure. It is not known whether exposure to sunlight might lead to skin irritation or cause one to break out in a rash or sunburn. If possible, patients should avoid direct exposure to the sun for long periods of time while participating in this clinical study. Protective clothing and sunglasses as well as sunscreen (SPF 30 or higher) should be used if exposed to sunlight. In addition, patients should not expose themselves to sun lamps, tanning booths, or tanning beds.

Most common side effects of the combination of galicraftor and navocraftor: Headache/Fatigue /Back pain/Constipation/Dry lips/Decreased urination/Nausea/Rash

Risks related to Study Procedures:

Blood Testing: may cause pain, bleeding, and/or bruising

Sweat collection: may cause tingling of the skin. The sticky pads may result in "irritation" of the skin. There is a remote possibility of a burn due to the test.

Lung Function Testing: may feel the need to cough, or feel a bit short of breath and lightheaded

5-day washout may lead to withdrawal symptoms

Where is the study run from?

St James's University Hospital (UK)

When is the study starting and how long is it expected to run for?

January 2022 to December 2022

Who is funding the study?

AbbVie Ltd (UK)

Who is the main contact?

Dr Daniel Peckham, daniel.peckham@nhs.net

Contact information

Type(s)

Principal investigator

Contact name

Dr Daniel Peckham

Contact details

St James's University Hospital

Beckett St

Leeds

United Kingdom

LS9 7TF

+44 113 206 7170

Daniel.Peckham@nhs.net

Additional identifiers

ClinicalTrials.gov (NCT)

NCT04853368

Clinical Trials Information System (CTIS)

2020-005805-25

Integrated Research Application System (IRAS)

1004477

Central Portfolio Management System (CPMS)

51119

Protocol serial number

M19-771

Study information

Scientific Title

A phase 2 study of galicafator/navocafator/ABBV-119 combination therapy in subjects with cystic fibrosis who are homozygous or heterozygous for the F508del mutation

Study objectives

The primary objective is to evaluate the safety, tolerability, and efficacy for galicafator/navocafator /ABBV-119 combination therapy in adult subjects with CF who are homozygous or heterozygous for the F508del mutation.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approval pending, HRA Fast Track REC, ref: 22/FT/0001

Study design

Interventional double blind randomized parallel group placebo controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Cystic Fibrosis

Interventions

Study doctors place participants in 1 of the 4 groups, called treatment arms. Each group receives a different treatment. Around 90 adult participants with a diagnosis of CF will be enrolled in the study at approximately 35 sites worldwide.

Participants in arm 1 will receive oral capsules of galicafator/navocafator dual combination for 28 days followed by galicafator/navocafator/ABBV-119 triple combination for 28 days.

Participants in arms 2 and 3 will receive the galicafator/navocafator/ABBV-119 triple combination or placebo for 28 days.

Participants in arm 4 will receive galicafator/navocafator/ABBV-119 triple combination therapy for

28 days.

For all study arms, galicafort, navocafort, will be given once daily and ABBV-119 twice a day.

Intervention Type

Drug

Phase

Phase II

Drug/device/biological/vaccine name(s)

galicafort, navocafort, ABBV-119

Primary outcome(s)

The primary endpoint is the absolute change from Baseline through Day 29 in percent predicted forced expiratory volume in 1 second (ppFEV1) measured using spirometry

Key secondary outcome(s)

Measured using spirometry unless noted otherwise:

1. Absolute change from Baseline through Day 29 in Sweat Chloride (SwCl) measured using sweat samples
2. Absolute change from Baseline through Day 29 in forced vital capacity [FVC]
3. Absolute change from Baseline through Day 29 in forced expiratory flow at mid-lung capacity [FEF25-75]
4. Relative changes from Baseline through Day 29 in ppFEV1
5. Relative changes from Baseline through Day 29 in FVC
6. Relative changes from Baseline through Day 29 in FEF25-75
7. Absolute change in CF Questionnaire-Revised (CFQ-R) respiratory domain score from Baseline through Day 29

Completion date

16/12/2022

Reason abandoned (if study stopped)

Objectives no longer viable

Eligibility

Key inclusion criteria

1. Confirmed clinical diagnosis of CF, and genotype homozygous for the F508del CFTR mutation for Cohort 1 and Cohort 3, heterozygous for F508del CFTR mutation and a minimal function mutation for Cohort 2 and Cohort 3.
2. ppFEV1 $\geq 40\%$ and $\leq 90\%$ of predicted normal for age, gender, and height (Global Lung Function Initiative [GLI] equations) at Screening.
3. No clinically significant laboratory values at Screening that would pose undue risk for the subject or interfere with safety assessments (per the investigator).
4. Absence of clinically significant abnormality detected on ECG regarding rate, rhythm, or conduction (e.g., QT interval corrected for heart rate using Fridericia's formula [QTcF] should be < 450 msec for males and < 460 msec for females).
5. Stable pulmonary status, i.e., no respiratory infections or exacerbations requiring a change in therapy (including antimicrobials) or causing an acute decline in ppFEV1 of $> 10\%$ from usual

ppFEV1 level within 4 weeks.

6. SwCl at screening visit must be ≥ 60 mmol/L for Cohort 1 and Cohort 2, and this criterion does not apply to Cohort 3.

7. No history of diseases aggravated or triggered by ultraviolet radiation and no history of abnormal reaction photosensitivity or photoallergy to sunlight, or artificial source of intense light, especially ultraviolet light.

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

1. Cirrhosis with or without portal hypertension (e.g., splenomegaly, esophageal varices) or history of clinically significant liver disease
2. History of malignancy within past 5 years (except for excised basal cell carcinoma of the skin with no recurrence, or treated carcinoma in situ of the cervix with no recurrence)
3. Recent (within the past 6 months) history of drug or alcohol abuse that might preclude adherence to the protocol, in the opinion of the investigator
4. Smoking or vaping tobacco or cannabis products within 6 months before Screening
5. History of solid organ or hematopoietic transplantation
6. History of known sensitivity to any component of the study drug
7. Need for supplemental oxygen while awake, or >2 L/minute while sleeping.
8. Evidence of active SARS-CoV-2 infection. If a subject has signs/symptoms suggestive of SARS CoV-2 infection, they should undergo molecular (e.g., polymerase chain reaction [PCR]) testing to rule out SARS-CoV-2 infection.

Date of first enrolment

28/07/2021

Date of final enrolment

16/12/2022

Locations

Countries of recruitment

United Kingdom

England

Scotland

Belgium

Canada

France

Hungary

Netherlands

Puerto Rico

Serbia

Slovakia

Spain

Study participating centre

The Adult Cystic Fibrosis Centre

Royal Papworth Hospital NHS FT

Papworth Road

Cambridge

United Kingdom

CB2 0AY

Study participating centre

Queen Elizabeth University Hospital

1345 Govan Road

Glasgow

United Kingdom

G51 4TF

Study participating centre

All Wales Adult Cystic Fibrosis Centre

Cardiff and Vale University Health Board

Penlan Road

Cardiff

United Kingdom

CF64 2XX

Study participating centre

King's College Hospital

Denmark Hill

London
United Kingdom
SE5 9RS

Study participating centre
Royal Brompton Hospital
Sydney Street
London
United Kingdom
SW3 6NP

Study participating centre
Manchester Adult Cystic Fibrosis Centre
Wythenshawe Hospital
Southmoor Road
Wythenshawe
Manchester
United Kingdom
M23 9LT

Study participating centre
Southampton General Hospital
Tremona Road
Southampton
United Kingdom
SO16 6YD

Sponsor information

Organisation
AbbVie (United Kingdom)

ROR
<https://ror.org/04tnbfn25>

Funder(s)

Funder type
Industry

Funder Name

AbbVie

Alternative Name(s)

AbbVie Inc., AbbVie U.S., AbbVie US, Allergan

Funding Body Type

Government organisation

Funding Body Subtype

For-profit companies (industry)

Location

United States of America

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are not expected to be made available.

IPD sharing plan summary

Not expected to be made available